The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
ApexOnco Front Page
Recent articles
Solstice Oncology acquires porustobart from Harbour Biomed.
ASH and SABCS approach.
The project has priority review, but deaths could raise eyebrows.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
An in vivo Car-T produced a 100% response rate – in three patients.
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
